Point mutation of C-terminal region of CD20 molecule predicts rituximab-induced complement-dependent cytotoxicity and clinical response to rituximab in non-Hodgkin's lymphoma.

被引：0
|
作者：
Terui, Y.
Mishima, Y.
Mishima, Y.
Yokoyama, M.
Hatake, K.
Sugimura, N.
Kojima, K.
Sakurai, T.
Takeuchi, K.
机构：
[1] CIH, Tokyo, Japan
[2] Morinaga Milk Co, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：437S / 437S
页数：1
相关论文
共 47 条
  • [31] Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma
    Scheidhauer, K
    Wolf, I
    Baumgartl, HJ
    von Schilling, C
    Schmidt, B
    Reidel, G
    Peschel, C
    Schwaiger, M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (10) : 1276 - 1282
  • [32] IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients
    Nguyen, DT
    Amess, JA
    Doughty, H
    Hendry, L
    Diamond, LW
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1999, 62 (02) : 76 - 82
  • [33] Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study).
    Martinelli, G
    Laszlo, D
    Conconi, A
    Rabascio, C
    Ferreri, AJ
    Pruneri, G
    Crosta, C
    Ponzoni, M
    Pedrinis, E
    Agazzi, A
    Zucca, E
    BLOOD, 2003, 102 (11) : 410A - 410A
  • [34] Phase I study of DEC-C2B8 [rituximab] in patients with relapsed or refractory B-cell [CD20+] non-Hodgkin's lymphoma in Japan
    Ogura, M
    Morishima, Y
    Kobayashi, Y
    Sasaki, Y
    Ohtsu, T
    Murate, T
    Kinoshita, T
    Tobinai, K
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 407 - 407
  • [35] Anti-CD20 monoclonal antibody (Rituximab) as single agent or in combination with cytotoxic chemotherapy induces molecular remissions in heavily pre-treated or newly diagnosed patients with follicular non-Hodgkin's lymphoma.
    Martin, S
    Kronenwett, R
    Niederste-Hollenberg, A
    Meckenstock, G
    Haas, R
    BLOOD, 2000, 96 (11) : 242B - 242B
  • [36] Treatment of patients with mantle cell and aggressive B-cell non-Hodgkin's lymphoma using the monoclonal anti-CD20 antibody rituximab (Rituxan™):: Evaluation of safety and response.
    Winkler, U
    Schulz, HR
    Klein, TO
    Jensen, M
    Manzke, O
    Schmitz, SH
    Rüdiger, T
    Müller-Hermelink, KH
    Diehl, V
    Engert, A
    BLOOD, 1999, 94 (10) : 270B - 270B
  • [37] R-DHAP - Preliminary safety and feasibility data of sequential high-dose chemotherapy with autologous stem cell support in combination with the anti-CD20 antibody rituximab in relapsed aggresive non-Hodgkin's lymphoma.
    Staak, JO
    Glossmann, JP
    Diehl, V
    Engert, A
    Josting, A
    BLOOD, 2002, 100 (11) : 299B - 300B
  • [38] Chimeric anti-CD20 monoclonal antibody (Rituximab; Mabtheraa) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: A phase III randomized intergroup clinical trial.
    Van Oers, MHJ
    Van Glabbeke, M
    Teodorovic, L
    Rozewicz, C
    Klasa, R
    Marcus, RE
    Wolf, M
    Kimby, E
    Hagenbeek, A
    BLOOD, 2004, 104 (11) : 169A - 169A
  • [39] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
    Anderson, DR
    GrilloLopez, A
    Varns, C
    Chambers, KS
    Hanna, N
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : 705 - 708
  • [40] Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
    Pawluczkowycz, Andrew W.
    Beurskens, Frank J.
    Beum, Paul V.
    Lindorfer, Margaret A.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    Taylor, Ronald P.
    JOURNAL OF IMMUNOLOGY, 2009, 183 (01): : 749 - 758
12345